Sentence examples for large scale clinical studies from inspiring English sources

Large scale clinical studies have demonstrated that cytogenetic abnormalities provide valuable information of prognostic relevance.

Although there are numerous in vitro, as well as in vivo data from animal studies, to date no information of large scale clinical studies exist that examines a correlation between circulating cytokine levels and asthma phenotypes or exacerbations of disease in different age groups.

No large scale clinical studies have been published on the immunological and virological effects of ARV drugs.

Based on this assumption, several inhibitors of CETP are currently under investigation in large scale clinical studies [ 23].

Here we describe such procedures which have been developed in the TEDDY study and which are applicable also to other large scale clinical studies.

The conflicting results obtained with PDE 5 inhibitors in the clinical setting require a thorough investigation in an experimental model prior to proceed to large scale clinical studies.

Large-scale clinical studies are needed to establish the translation of pre-clinical findings to the clinical arena.

Although there is no sufficient evidence to believe that granulocyte colony-stimulating factor (G-CSF) may be a useful treatment in patients with ST segment elevation myocardial infarction (STEMI) who undergo primary percutaneous coronary intervention, further large-scale clinical studies are needed to examine the exact role of G-CSF in the management of those patients.

Additional large-scale clinical studies are required in order to better define the exact indications, protocols, and expected prognosis of these novel treatments (Tsesis et al. 2015).

The clinical importance of the P2Y12 receptor as a mediator of platelet activation has become evident in several large-scale clinical studies and inhibition of the P2Y12 receptor with clopidogrel is one of the cornerstones in treatment and prevention of acute coronary syndromes [9].

Although the shift towards dual IFN-γ/IL-2-secreting T cells is emerging as a promising biomarker of treatment response, large-scale clinical studies are now required to determine its clinical utility and should include patients who fail to respond to treatment such as those with multidrug-resistant TB.